uniQure Shares Rise on FDA Accelerated Pathway for AMT-130

uniQure shares increased by 6.4 percent following agreement from regulatory authorities on an accelerated approval pathway for AMT-130, its gene therapy targeting Huntington’s disease. The framework provides a clearer clinical development route for the investigational treatment.

The clinical milestone coincides with a recent capital raise securing $259 million to fund ongoing confirmatory trials and potential future commercialization efforts. Despite these developments, the company reported a wider net loss in recent financial disclosures.

Medical researchers indicate that the accelerated pathway underscores the urgency for effective treatments in neurodegenerative disorders. Observers note that successful execution of confirmatory trials remains critical for final regulatory clearance.